Skip to content
YCS20· AI

Nephrogen

Curative genetic medicines for kidney diseases

ActiveChecked 18h ago
Batch
S20
Status, per YC
Active
Team size
5
HQ
New York City, NY
In S20209 companies, 28% AI
nephrogenbiotech.comYC profile

Founders

Not read from YC yet; the weekly run fills these in.

Same space

About Nephrogen

Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.

New York City, NY, USA

Nephrogen: questions

Which YC batch was Nephrogen in?

Nephrogen was in Y Combinator's Summer 2020 batch (S20).

Is Nephrogen still active?

Y Combinator lists Nephrogen as active.

Where is Nephrogen based?

Nephrogen lists New York City, NY, USA as its location on YC's directory.

Not affiliated with Y Combinator. From YC's public directory. Logos via logo.dev; trademarks belong to their owners.

Weekly: new YC data, AI and devtools companies and status changes, Mondays.